LLY·Eli Lilly and Company

Eli Lilly announced positive topline results from its Phase 3 ADorable-1 trial for EBGLYSS (lebrikizumab-lbkz) in pediatric patients with moderate-to-severe atopic dermatitis. The study met its primary and key secondary endpoints, demonstrating significant skin improvement and itch relief, with a safety profile consistent with prior studies. This development reinforces EBGLYSS's potential in a new patient population, suggesting future market expansion. Looking at recent financial performance, Eli Lilly reported robust Q4 and full-year 2025 results, driven primarily by its tirzepatide franchise, encompassing Mounjaro and Zepbound. Q4 revenue surged 43% year-over-year to $19.3 billion, with full-year revenue reaching $65.2 billion. This strong volume-driven growth, despite some pricing pressures impacting obesity treatment access, positions the company as a pharmaceutical leader. Institutional investors continue to show interest, with Community Bank N.A. increasing its LLY holdings by 28% in Q3, reflecting growing confidence. Other asset managers have also adjusted positions, with multiple funds reporting buying or increasing stakes in LLY. Meanwhile, OrbiMed Advisors, a significant holder, maintains LLY as a core investment, representing 6.7% of its reported assets under management, even as they adjusted other holdings. Investors will be watching for further updates on EBGLYSS's regulatory path and continued performance of the tirzepatide franchise.